Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity. On February 3, 2026, 22,025 restricted stock units converted into an equal number of common shares at an exercise price of $0. To cover tax withholding on this vesting, 6,449 common shares were withheld by the company at $3.47 per share.
After these transactions, Balthaser directly owned 185,755 shares of common stock and 66,075 restricted stock units, which continue to vest in four equal annual installments starting from February 3, 2025, contingent on his continued service.
Aclaris Therapeutics, Inc.'s Chief Business Officer reported multiple equity compensation events on February 1, 2026. Several restricted stock unit (RSU) awards were exercised (transaction code M), delivering 11,250, 7,500, and 14,750 shares of common stock in separate transactions.
The filing also reports a transaction coded F, where 10,686 shares were withheld at $3.51 per share to cover tax obligations tied to RSU vesting. The RSU grants vest in four equal annual installments starting on February 1 of 2022, 2023, and 2024, subject to continued service. This amendment corrects a prior filing that mistakenly referenced a February 1, 2025 transaction due to a filing platform error.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity involving restricted stock units and common stock. On February 1, 2026, 14,750 restricted stock units were converted into an equal number of shares of Aclaris common stock, reflecting previously granted equity awards.
To cover related tax withholding on this vesting, the issuer withheld 4,984 shares of common stock at $3.51 per share. Following these transactions, Balthaser directly held 170,179 shares of common stock and 29,500 restricted stock units. The remaining restricted stock units vest in four equal annual installments beginning on the first anniversary of February 1, 2024, contingent on his continued service.
Aclaris Therapeutics Chief Business Officer James Loerop reported an automatic share withholding related to equity compensation. On February 1, 2025, the issuer withheld 15,980 shares of common stock at $2.48 per share to cover his tax obligations upon restricted stock unit vesting.
After this transaction, Loerop beneficially owned 102,773 shares of Aclaris common stock in direct ownership. The filing is an amendment that corrects the previously reported number of shares withheld, which will change the reported beneficial ownership amounts in later filings.
Aclaris Therapeutics’ chief business officer filed an amended insider share report to correct how many shares were withheld for taxes on vested restricted stock units. On 02/01/2025, the company withheld 15,980 shares of common stock at $2.48 per share to cover tax obligations. After this correction, the officer directly held 102,773 shares of Aclaris common stock. The amendment clarifies the prior disclosure and will adjust reported beneficial ownership in future filings.
BlackRock, Inc. filed an amended Schedule 13G reporting a sizable passive stake in Aclaris Therapeutics, Inc. common stock. As of the event date of 12/31/2025, BlackRock reported beneficial ownership of 6,700,629 Aclaris shares, representing 6.2% of the outstanding common stock.
BlackRock reported sole voting power over 6,626,227 shares and sole dispositive power over 6,700,629 shares, with no shared voting or dispositive power. The filing notes that various underlying clients or shareholders have rights to dividends or sale proceeds, but no individual person has more than five percent of Aclaris’s total outstanding common shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Aclaris, consistent with a passive institutional investment position.
Aclaris Therapeutics, Inc. furnished an updated corporate overview presentation as part of a current report under Regulation FD. The presentation is attached as Exhibit 99.1 and is also available on the company’s website, providing an overview of its business for investors and other stakeholders. The company states that this material is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings unless specifically referenced.
Biosion, Inc. and its wholly owned subsidiary Bonita Biotech (HK) Limited report their ownership of Aclaris Therapeutics, Inc. common stock on an amended Schedule 13G. Bonita Biotech (HK) Limited holds 11,281,950 shares of common stock, representing 9.4% of the class, with sole voting and dispositive power.
The filing explains that a warrant originally held by Biosion, Inc. for 11,281,985 shares was assigned to Bonita Biotech (HK) Limited on December 9, 2025 and then exercised on a cashless basis, resulting in issuance of 11,281,950 shares on December 15, 2025. The 9.4% figure is based on 119,624,542 shares of Aclaris common stock, which includes 108,342,592 shares outstanding as referenced in a prior Form 8-K and the new shares issued to Bonita Biotech (HK) Limited. The reporting persons certify the shares are not held to change or influence control of Aclaris.
Aclaris Therapeutics (ACRS) reported Q3 2025 results. Total revenue was $3.299 million (contract research $0.485M; licensing $2.814M). Operating expenses rose on pipeline investment, with R&D at $13.028 million and G&A at $4.871 million. The company recorded non‑cash royalty income of $0.716 million from the OLUMIANT royalty sale structure.
Net loss was $14.614 million versus $7.586 million a year ago, reflecting higher development spend. Year‑to‑date, net loss was $45.128 million. The balance sheet showed cash, cash equivalents and marketable securities of $167.2 million as of September 30, 2025, and stockholders’ equity of $120.1 million. Management states its resources are sufficient for more than 12 months from issuance. Shares outstanding were 108,345,239 as of October 31, 2025.
Segment data highlight therapeutics as the primary driver: Q3 R&D included bosakitug $3.062M, ATI‑2138 $1.469M, and ATI‑052 $1.837M, alongside discovery $2.340M. Deferred income related to the royalty sale was $3.925M current and $17.492M non‑current.
Aclaris Therapeutics, Inc. furnished an 8-K to share its latest financial update. The company issued a press release announcing financial results for the quarter and nine-month period ended September 30, 2025. This update is provided to keep investors informed about recent operating performance and financial condition.
The press release is attached as Exhibit 99.1 and is furnished rather than filed, which means it is not automatically incorporated into other SEC reports unless specifically referenced. The 8-K is signed on behalf of the company by Chief Financial Officer Kevin Balthaser.